These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 22287205)
1. Targeting the enhancer of zeste homologue 2 in medulloblastoma. Alimova I; Venkataraman S; Harris P; Marquez VE; Northcott PA; Dubuc A; Taylor MD; Foreman NK; Vibhakar R Int J Cancer; 2012 Oct; 131(8):1800-9. PubMed ID: 22287205 [TBL] [Abstract][Full Text] [Related]
2. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma. Vo BT; Li C; Morgan MA; Theurillat I; Finkelstein D; Wright S; Hyle J; Smith SMC; Fan Y; Wang YD; Wu G; Orr BA; Northcott PA; Shilatifard A; Sherr CJ; Roussel MF Cell Rep; 2017 Mar; 18(12):2907-2917. PubMed ID: 28329683 [TBL] [Abstract][Full Text] [Related]
3. MELK and EZH2 Cooperate to Regulate Medulloblastoma Cancer Stem-like Cell Proliferation and Differentiation. Liu H; Sun Q; Sun Y; Zhang J; Yuan H; Pang S; Qi X; Wang H; Zhang M; Zhang H; Yu C; Gu C Mol Cancer Res; 2017 Sep; 15(9):1275-1286. PubMed ID: 28536141 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667 [TBL] [Abstract][Full Text] [Related]
5. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619 [TBL] [Abstract][Full Text] [Related]
6. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Sasaki D; Imaizumi Y; Hasegawa H; Osaka A; Tsukasaki K; Choi YL; Mano H; Marquez VE; Hayashi T; Yanagihara K; Moriwaki Y; Miyazaki Y; Kamihira S; Yamada Y Haematologica; 2011 May; 96(5):712-9. PubMed ID: 21228036 [TBL] [Abstract][Full Text] [Related]
7. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699 [TBL] [Abstract][Full Text] [Related]
9. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Wei Y; Chen YH; Li LY; Lang J; Yeh SP; Shi B; Yang CC; Yang JY; Lin CY; Lai CC; Hung MC Nat Cell Biol; 2011 Jan; 13(1):87-94. PubMed ID: 21131960 [TBL] [Abstract][Full Text] [Related]
10. Leading medulloblastoma to a differentiation end. Nör C; Ramaswamy V Cancer Cell; 2024 Aug; 42(8):1331-1333. PubMed ID: 39137724 [TBL] [Abstract][Full Text] [Related]
11. Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Kemp CD; Rao M; Xi S; Inchauste S; Mani H; Fetsch P; Filie A; Zhang M; Hong JA; Walker RL; Zhu YJ; Ripley RT; Mathur A; Liu F; Yang M; Meltzer PA; Marquez VE; De Rienzo A; Bueno R; Schrump DS Clin Cancer Res; 2012 Jan; 18(1):77-90. PubMed ID: 22028491 [TBL] [Abstract][Full Text] [Related]
12. EZH2-regulated DAB2IP is a medulloblastoma tumor suppressor and a positive marker for survival. Smits M; van Rijn S; Hulleman E; Biesmans D; van Vuurden DG; Kool M; Haberler C; Aronica E; Vandertop WP; Noske DP; Würdinger T Clin Cancer Res; 2012 Aug; 18(15):4048-58. PubMed ID: 22696229 [TBL] [Abstract][Full Text] [Related]
13. EZH2 is essential for glioblastoma cancer stem cell maintenance. Suvà ML; Riggi N; Janiszewska M; Radovanovic I; Provero P; Stehle JC; Baumer K; Le Bitoux MA; Marino D; Cironi L; Marquez VE; Clément V; Stamenkovic I Cancer Res; 2009 Dec; 69(24):9211-8. PubMed ID: 19934320 [TBL] [Abstract][Full Text] [Related]
14. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Li H; Cai Q; Godwin AK; Zhang R Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743 [TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412 [TBL] [Abstract][Full Text] [Related]
16. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Fujii S; Ochiai A Cancer Sci; 2008 Apr; 99(4):738-46. PubMed ID: 18377425 [TBL] [Abstract][Full Text] [Related]
17. Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Derfoul A; Juan AH; Difilippantonio MJ; Palanisamy N; Ried T; Sartorelli V Carcinogenesis; 2011 Nov; 32(11):1607-14. PubMed ID: 21828058 [TBL] [Abstract][Full Text] [Related]